Nitrospray (Glyceryl Trinitrate)

Glyceryl trinitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, raising cyclic GMP levels, which relaxes smooth muscle in veins and arteries. This reduces cardiac preload and afterload, lowering myocardial oxygen demand and easing angina.

The exact dose of Nitrospray is determined by the prescribing clinician based on the individual’s condition and response. Typically, a single sublingual spray is administered at the onset of chest pain, and additional doses may be given if needed, following the prescriber’s instructions.

Safety data for glyceryl trinitrate during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss possible risks with the patient.

To place an order, submit an enquiry on the Nitrospray product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitrospray belongs to the organic nitrate class, offering rapid onset of action through nitric‑oxide mediated vasodilation. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle and are preferred for immediate symptom relief, whereas other classes are often used for long‑term rate control and prevention.

Nitrospray should be stored at ambient temperature, preferably below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the spray nozzle remains clean. Do not expose the product to extreme heat or freeze it.

Nitrospray is administered sublingually. The patient should hold the device upright, press the actuator to release a spray onto the tongue, and keep the spray under the tongue for at least 30 seconds without swallowing. Food or drink should be avoided for a few minutes to allow full absorption.

The most serious adverse events include severe hypotension, which can lead to fainting or syncope, and rare cases of methemoglobinemia, a condition that reduces oxygen delivery in the blood. Patients should be monitored for sudden drops in blood pressure and any signs of dizziness or loss of consciousness.

Nitrospray is contraindicated in patients with severe hypotension, recent use of phosphodiesterase‑5 inhibitors (e.g., sildenafil), known hypersensitivity to organic nitrates, or those with certain forms of cardiogenic shock. Clinicians should review the patient’s medical history before prescribing.